Home / Pipeline / Epcoritamab + Epcoritamab, tafasitamab and lenalidomide Products Epcoritamab + Epcoritamab, tafasitamab and lenalidomide
Epcoritamab + Epcoritamab, tafasitamab and lenalidomide Phase 2 Recruiting ⚡ Active Interest: 42/100
Aug 4, 2025 → Dec 1, 2031
About Epcoritamab + Epcoritamab, tafasitamab and lenalidomide Epcoritamab + Epcoritamab, tafasitamab and lenalidomide is a phase 2 stage product being developed by AbbVie for Large B Cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07126236. Target conditions include Large B Cell Lymphoma.
What happened to similar drugs? 1 of 20 similar drugs in Large B Cell Lymphoma were approved
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT07126236 Phase 2 Recruiting Aug 4, 2025 Dec 1, 2031 Large B Cell Lymphoma
Product Company Stage Hype Score Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX) Eli Lilly Phase 2 rituximab Celltrion Phase 1 YM155 Astellas Pharma Phase 2 enzastaurin + gemcitabine + rituximab + oxaliplatin Eli Lilly Phase 2 Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Johnson & Johnson Phase 2 VELCADE + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Johnson & Johnson Phase 2 Epcoritamab + Epcoritamab, lenalidomide and rituximab AbbVie Phase 2 Epcoritamab + Rituximab + Lenalidomide + Oxaliplatin + Gemcitabine AbbVie Phase 3 ABBV-525 AbbVie Phase 1 rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + rituximab and lenalidomide + rituximab and bendamustine + rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin + gemcitabine and oxaliplatin + Epcoritamab + rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone + Lenalidomide + rituximab, ifosfamide, carboplatin, and etoposide phosphate + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Rituximab and Lenalidomide + Epcoritamab AbbVie Phase 1/2 Copanlisib + Venetoclax AbbVie Phase 1/2 Epcoritamab + Investigator's Choice Chemotherapy AbbVie Phase 3 Epcoritamab + Lenalidomide AbbVie Phase 2 Venetoclax + Selinexor AbbVie Phase 1 Epcoritamab AbbVie Phase 1 Loncastuximab Tesirine and Epcoritamab AbbVie Phase 2 Epcoritamab + Investigator's Choice Chemotherapy AbbVie Phase 3 bendamustine + navitoclax + rituximab AbbVie Phase 2 Epcoritamab AbbVie Phase 2 Epcoritamab (monotherapy) + Epcoritamab + Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + Gemcitabine and oxaliplatin + Epcoritamab (maintenance) + Rituximab and lenalidomide AbbVie Phase 1/2